Oral 5‐aminosalicylic acid vs placebo: Serious adverse events
- Population
- Patients with quiescent ulcerative colitis
- Intervention
- Oral 5‐aminosalicylic acid
- Comparison
- placebo
- Outcome
- Serious adverse events
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Oral 5‐aminosalicylic acid vs placebo Serious adverse events · people with quiescent UC Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty). Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane Headline outcomes only | RR 0.6 [0.19, 1.84] | 3 studies · 826 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Oral 5‐aminosalicylic acid vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) · Patients with quiescent ulcerative colitis · 1 review
- Oral 5‐aminosalicylic acid vs sulfasalazine · Patients with quiescent ulcerative colitis · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.